beraprost

Small moleculeexperimental

Beraprost is a pharmaceutical drug used in several Asian countries, including Japan and South Korea, as a vasodilator and antiplatelet agent. It is classified as a prostacyclin analog. — Wikipedia

Clinical trial activity

19 trials · 9 clinical orgs · 0 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started Oct 1, 2005 (NCT02480751)

Timeline

2000s

Jan 1, 2005
Earliest Phase 2 Sponsor(trial)
Jan 1, 2008
Earliest Phase 1 Sponsor(trial)
Jan 1, 2009
Earliest Phase 3 Sponsor(trial)

Indications

Approved for

Hypertension, Pulmonary

Studied for

Mechanism of action

Prostanoid IP receptorAGONIST
PTGIR agonist
- Prostacyclin receptor (PTGIR) ↗

Chemistry & pharmacology

Loading structure…

SMILES

CC#CCC(C)[C@H](O)/C=C/[C@@H]1[C@H]2c3cccc(CCCC(=O)O)c3O[C@H]2C[C@H]1O

Mol. weight: 398.5 g/mol
Lipinski Ro5: Pass
Rule of 3: No
Chirality: Racemic Mixture
Inorganic: No
Polymer: No

Oral

Parenteral

Topical

Sources

Also known as

1h-cyclopenta(b)benzofuran-5-butanoic acid, 2,3,3a,8b-tetrahydro-2-hydroxy-1-(3-hydroxy-4-methyl-1-octen-6-ynyl)-, monosodium salt
4-(1,2,3a,8b-tetrahydro-2-hydroxy-1-(3-hydroxy-4-methyloct-6-yne-1-enyl)-5-cyclopenta(b)benzofuranyl)butyrate
aps-314d
aps-314d
beraprost
beraprost
beraprost
beraprost
beraprost
beraprost
beraprost
beraprost sodium
beraprost sodium
beraprost sodium
beraprost sodium
beraprost sodium
mdl-201129
mdl-201129
mdl-201229
mdl-201229
ml-1129
ml-1129
ml-1229
ml-1229
procylin
procylin
procylin
procylin
procylin
procylin
prostaglandin i2 analogue
trk 100
trk-100
trk-100
trk-100
trk-100stp
trk-100stp

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT05103813	Early Phase 1 (Phase 1)	Nov 1, 2021	Shenzhen University
NCT03657095	Phase 3	Dec 31, 2018	Lung Biotechnology PBC
NCT03682952	Phase 4	Feb 1, 2018	Xuzhou Medical University
NCT03142360	N/A	Apr 5, 2017	Yonsei University
NCT03431649	Phase 4	Apr 1, 2017	Dr. Soetomo General Hospital
NCT01908699	Phase 3	May 1, 2013	Lung Biotechnology PBC
NCT01796418	N/A	Mar 1, 2013	Astellas, Hallym University, Seoul National University
NCT01458236	Phase 3	Nov 1, 2011	Lung Biotechnology PBC
NCT01423435	Phase 1	Aug 1, 2011	Astellas, Toray Industries, Inc
NCT01443429	Phase 1	Aug 1, 2011	Toray Industries, Inc
NCT02786979	Phase 4	Jul 1, 2010	Astellas
NCT01090037	Phase 2/Phase 3 (Phase 3)	Mar 1, 2010	Astellas, Toray Industries, Inc
NCT00990314	Phase 2	Nov 1, 2009	Lung Biotechnology PBC
NCT00989963	Phase 2	Nov 1, 2009	Lung Biotechnology PBC
NCT01056835	Phase 3	Jun 1, 2009	Seoul National University
NCT00792571	Phase 2	Feb 1, 2009	Lung Biotechnology PBC
NCT00781885	Phase 2	Jan 1, 2009	Lung Biotechnology PBC
NCT00719758	Phase 1	Jun 1, 2008	Astellas, Toray Industries, Inc
NCT02480751	Phase 2	Oct 1, 2005	Astellas, Toray Industries, Inc

Showing 19 of 19 trials

Page 1 / 1

Organizations

Research & Development (9)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Lung Biotechnology PBC	For profit	7	7	2	2009
Astellas	For profit	6	3	5	2005
Toray Industries, Inc	For profit	5	3	3	2005
Seoul National University	Academic/Hospital	2	2	2	2009
Dr. Soetomo General Hospital	Academic/Hospital	1	1	1	2017
Hallym University	Academic/Hospital	1	0	1	2013
Shenzhen University	Academic/Hospital	1	1	1	2021
Xuzhou Medical University	Academic/Hospital	1	1	1	2018
Yonsei University	Academic/Hospital	1	1	1	2017

9 organizations

Page 1 / 1